NCT05451290进行中（未招募）2 期
Camrelizumab Plus Apatinib Combined With GEMOX (Gemcitabine and Oxaliplatin ) in the Perioperative Treatment of Locally Advanced Biliary Tract Malignancies: A Prospective, Multicenter, Phase Ⅱ Study
First Affiliated Hospital of Zhejiang University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年11月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- 1-year EFS rate
研究概览
简要总结
This is a phase II open-label, one-arm, multicenter study aimed to explore the efficacy and safety of perioperative (neoadjuvant and adjuvant) treatment for patients with advanced biliary tract carcinoma.
详细描述
Enrolled participants should be treated with neoadjuvant camrelizumab and apatinib and GEMOX, after surgery, be treated with adjuvant camrelizumab and S-1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent document must be signed.
- •Aged 18-75 years old, both genders.
- •Pathologically confirmed biliary tract adenocarcinoma and haven't been treated before.
- •An Eastern Cooperative Oncology Group performance status of 0 to
- •Locally advanced biliary tract adenocarcinoma confirmed by MDT discussion.
- •The function of vital organs meets the following requirements:
- •the blood ANC count≥1.5x109 /L; hemoglobin ≥ 90 g/L，the blood platelet count≥80 x109 /L, total bilirubin ≤ 1.5 x ULN, ALT and AST ≤3 x ULN(< 5 x ULN for patients with live metastasis), serum creatinine≤1.5 x ULN, endogenous creatinine clearance rate ≥45ml/min.
- •At least 1 measurable lesion as defined by RECIST 1.
- •Women of reproductive age need to take effective contraceptive measures during and within 3 months of the end of medication.
- •Subjects should have good compliance and cooperate with the follow-up.
排除标准
- •Subject has any active autoimmune disease or history of autoimmune disease will not be included, nor will patients with active tuberculosis or hepatitis or HIV.
- •Subjects with illness or medical conditions that could jeopardize their sugery, such as severe cardiopulmonary insufficiency and coagulation disorders, cannot be enrolled.
- •Subjects with active malignancies other than BTC within 5 years should be excluded, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix and superficial bladder cancer [Ta, Tis & T1] and papillary thyroid cancer.
- •Any unstable systemic disease which might need systemic treatment should not be enrolled (including active infection, liver or renal disease, metabolic disease, acute cerebral infarction or hemorrhage), or serious co-morbidities that by the judgment of the investigator, may compromise the patient's safety or impair the patient's ability to complete the study.
- •Subjects who have significant cardiovascular events should not be enrolled, for example: congestive heart failure > NYHA class 2, unstable angina, active coronary artery disease (CAD) (only allow the subjects with presence of myocardial infarction more than 1 year prior to study); severe arrhythmias in need of treatment (only allow those been treated with β-blockers or digoxin) or uncontrolled hypertension.
- •Subjects with history of neurological or psychiatric disease, including epilepsy or dementia or diseases alike should not be enrolled.
- •Subjects with interstitial lung disease or a history of interstitial pneumonia should not be enrolled.
- •Subjects who had participated in other anti-tumor clinical trials within 4 weeks prior to enrollment should be avoided.
- •Subjects who had used PD-1/PD-L1 or other antitumor immunotherapeutic agents prior to enrollment should be avoided.
- •The following subjects should be avoided: pregnant or lactating women; those who have childbearing potential and unwilling or unable to use effective contraception measures.
- •Other circumstances that could affect the trial or the result of the study judged by the investigator.
研究组 & 干预措施
treatment arm
Experimental
干预措施: Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur (Drug)
结局指标
主要结局
1-year EFS rate
时间窗: 1 year
EFS was defined as the time from the first administration of study treatment to the first occurrence of any of the following events: disease progression that precluded surgical resection, disease recurrence after curative-intent surgery, disease progression in patients who did not undergo surgery, or death from any cause. 1-year EFS rate was the incidence rate of event-free survival within one year.
次要结局
- EFS(up to 5 years)
- OS(up to 5 years)
- adverse event(up to 2 years)
- R0 resection rate(up to 2 years)
- Major pathologic response (MPR)(up to 2 years)
- ORR(up to 2 years)
- DCR(up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaAdvanced Gastric CarcinomaNCT04948125Henan Cancer Hospital20
Unknown
2 期
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic CarcinomaPancreatic CancerNCT04415385Zhejiang Cancer Hospital48
已完成
2 期
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaResectable Hepatocellular CarcinomaNCT04701060Tianjin Medical University Cancer Institute and Hospital31
Unknown
2 期
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerSmall Cell Lung CarcinomaNCT04901754Henan Cancer Hospital38
尚未招募
2 期
Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaNCT05189184The First Affiliated Hospital of Zhengzhou University30